Valtrex Shortage: What Providers and Prescribers Need to Know in 2026

Valacyclovir (Valtrex) is not on the FDA Drug Shortage Database or the ASHP shortage list as of 2026. However, prescribers are increasingly fielding calls from patients who cannot fill their valacyclovir prescriptions at local pharmacies. This guide summarizes the current supply situation, the clinical implications of treatment delays, therapeutic alternatives with dosing guidance, and practical tools to help your patients get timely treatment.

Current Supply Status (2026)

Valacyclovir is produced by multiple generic manufacturers and is broadly available at the wholesale level. The challenges are downstream:

Pharmacy-level stockouts occur due to lean inventory practices and high prescription volume exceeding weekly restocking orders.

Strength-specific gaps: The 500 mg tablet is by far the most-dispensed strength; it runs out more frequently than the 1 g tablet.

Spillover demand: IV acyclovir has been in intermittent shortage since 2020, prompting some inpatient teams to switch stable patients to oral valacyclovir. This adds to community pharmacy demand.

Telehealth prescribing volume: A substantial portion of valacyclovir prescriptions now originate from telehealth platforms. Some of these are sent to pharmacies that are not equipped for the resulting demand spikes.

Why Timing Matters: Clinical Implications of Delayed Treatment

The antiviral window for herpes infections is narrow. Your patients need to understand this — and so does your front desk team when triaging calls about availability:

Herpes zoster (shingles): Antiviral therapy must begin within 72 hours of rash onset for maximal benefit. Delays beyond this window significantly reduce efficacy and increase the risk of postherpetic neuralgia (PHN), a chronic pain condition.

Recurrent genital herpes (episodic): Episodic therapy is most effective when initiated within 24 hours of prodromal symptoms. Patients often call for refills at onset — a delay of even 24–48 hours can reduce the clinical benefit substantially.

Cold sores (herpes labialis): Single-day treatment (2 g twice 12 hours apart) works only when started at the prodromal stage.

Therapeutic Alternatives: Dosing Reference for Prescribers

When valacyclovir is unavailable, the following alternatives are clinically equivalent for most indications. Dosing is NOT 1:1 — write a new prescription specifying the correct regimen.

Acyclovir (generic Zovirax) — First-Line Alternative:

Shingles: 800 mg 5 times daily × 7–10 days

Primary genital herpes: 400 mg 3 times daily × 7–10 days (or 200 mg 5 times daily × 10 days)

Recurrent genital herpes (episodic): 400 mg 3 times daily × 5 days

Suppressive therapy: 400 mg twice daily (ongoing)

Cold sores: 400 mg 5 times daily × 5 days

Famciclovir (generic Famvir) — Alternative for Shingles and Recurrent Genital Herpes:

Shingles: 500 mg 3 times daily × 7 days

Recurrent genital herpes (episodic): 1,000 mg twice daily × 1 day, OR 500 mg once then 250 mg twice daily × 2 days

Suppressive therapy: 250 mg twice daily

Note: Famciclovir is NOT FDA-approved for initial-episode genital herpes

Always adjust doses for renal impairment (creatinine clearance <50 mL/min) regardless of which antiviral is chosen.

Practice-Level Strategies to Minimize Patient Disruption

Pre-authorize an alternative on the original prescription. When prescribing valacyclovir, note in the pharmacy comments or call ahead: "If unavailable, may substitute acyclovir at equivalent dose." This saves the patient a call-back.

Send electronic prescriptions to pharmacies known to stock it. Ask your staff to maintain a short list of pharmacies in your area with good antiviral inventory, updated by patient feedback.

Recommend medfinder to patients at time of prescribing. For patients with recurrent herpes, inform them that if they can't fill quickly, they can use medfinder to identify which nearby pharmacies have the medication available.

Consider 90-day suppressive therapy prescriptions. For patients on daily valacyclovir, a 90-day mail-order supply dramatically reduces the frequency of refill-related stockout exposure.

How medfinder Can Help Your Patients

medfinder is a paid service that contacts pharmacies on a patient's behalf to identify which ones currently have their medication in stock. The patient provides their medication, dosage, and location — medfinder does the calling and texts the results. This is particularly valuable for your shingles and acute outbreak patients who cannot afford a 24–48 hour delay. Visit medfinder.com/providers to learn more about how medfinder can support your practice.

Summary for Prescribers

Valacyclovir is NOT in a formal shortage — but pharmacy-level stockouts are common in 2026

Treatment delays can have significant clinical consequences, especially for shingles (72-hour window)

Acyclovir is the most direct alternative — same clinical outcomes, higher dosing frequency

Famciclovir is an alternative for shingles and recurrent genital herpes — not for first-episode genital herpes

Consider proactive steps: pre-note alternatives, 90-day supplies, and medfinder for acute cases